Supplementary Material for: The clinical efficacy evaluation of the KHA-200 hemoperfusion device in the treatment of end-stage renal disease patients undergoing blood purification therapy

Objective: To assess the impact of employing the KHA-200 hemoperfusion device in conjunction with hemodialysis therapy in the elimination of serum solutes among maintenance hemodialysis patients. Methods: A total of ninety-two maintenance hemodialysis (MHD) patients from our hospital's hemodialysis center were judiciously chosen and allocated randomly into two groups: the conventional hemodialysis group, serving as the control group, and the group utilizing the KHA-200 hemoperfusion device in combination with hemodialysis, denoted as the experimental group, in a 1:1 ratio. We compared variations in serum solute indices, including blood urea nitrogen, creatinine, potassium, calcium, phosphorus, high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), β2-microglobulin (β2-MG), parathyroid hormone (PTH), homocysteine (Hcy),albumin,both prior to and post-treatment.Meanwhile, the comparison of the serum solute clearance rates in the two groups was performed. Results: Following treatment, both groups exhibited substantial reductions in blood urea nitrogen, creatinine, uric acid, potassium, phosphorus, PTH, and Hcy (p 0.05). Conversely, the experimental group demonstrated a significant effect on the elimination of IL-6 and β2-MG (p < 0.001). Furthermore, the experimental group's performance in reducing blood phosphorus, PTH, IL-6, β2-MG and Hcy was significantly superior to that of the control group (p < 0.05). Moreover, the reduction in systolic blood pressure in the experimental group was better than in the control group. Conclusion: Employing the KHA-200 hemoperfusion device in tandem with hemodialysis excels in removing blood phosphorus and certain medium-sized uremic toxins, including PTH, IL-6,β2-MG and Hcy surpassing the performance of conventional hemodialysis.